$QURE· SEC filing ·

QURE Reports $586.6M Cash, $11.2M Revenue, +12% YoY, Advances AMT-130 FDA Type B Meeting, UK MAA Q3 2026, AMT-260 Phase I/IIa Data June 2026, AMT-191 Fabry Data Shows 82x Enzyme Activity, All Patients Off ERT

uniQure N.V. · PHARMACEUTICAL PREPARATIONS · Now $28.22

+31% in 7d after detection

Post-detection moves

1h
1d
+7.8%
3d
+31%
7d
+31%
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS